Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 23, 2017
Pharmacy Choice - News - Generic Drugs - June 23, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 54     Next >>     Go To Page:

6/23/17 - Biogen's IMRALDI, an Adalimumab Biosimilar Candidate Referencing Humira, Granted Positive Opinion by Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for IMRALDI , an adalimumab biosimilar candidate referencing Humira . 1 The positive opinion will now be referred to the European Commission, which grants marketing authorization for medicines in the European Union. Today, the anti-
6/23/17 - Bipartisan Group of Members of Senate Judiciary Committee Urge FDA Commissioner to Address Abuses in Regulatory Process That Delay Competition, Increase Prescription Drug Costs
Commissioner Gottlieb recently stated that the FDA will take measures to curb anticompetitive abuses of its regulatory process for the approval of generic drugs. In their letter, the senators advocate for their legislative solution and ask Commissioner Gottlieb to detail the regulatory actions the FDA can and cannot take to address strategies that.
6/23/17 - Credence Research: Global Biosimilars Market Size Is Expected To Reach US$ 25.83 Bn By 2025 : Credence Research
The latest market report published by Credence Research, Ltd. "Global Biosimilars Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017- 2025," the Biosimilars market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83 Bn by 2025, expanding at a CAGR of 23.1% from 2017 to 2025.. Browse t
6/23/17 - Donald Trump Softens Stance on Drug Prices, Sends Biotech Stocks Soaring [Tehran Times (Iran)]
Donald Trump campaigned on reining in sky-high drug prices, and as recently as January, he said the industry was "getting away with murder." In the U.S., low-cost generic drugs represent nearly 90% of prescription-drug volume, yet high-cost specialty drugs used in indications such as cancer account for an increasingly larger share of total spending
6/23/17 - Dr. Reddy's Laboratories Announces the Launch of Bivalirudin for Injection in the U.S. Market
By a News Reporter-Staff News Editor at Drug Week Dr. Reddy's Laboratories Ltd. announced that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax for Injection, approved by the U.S. Food and Drug Administration. The Angiomax brand and generic had U.S. sales of approximately $198 mill
6/23/17 - Jacobson Pharma Announces 2017 Annual Results
Jacobson Pharma Corporation Limited, a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries for the year ended 31 March 2017. These annual results are the first since the company's listing in Hong Ko
6/23/17 - Maine Senate Passes Jackson's Bill to Lower Drug Costs
The Maine Senate Democrats issued the following news:. As the cost of prescription drugs continues to rise faster than wages and inflation alike, the Maine Senate on Thursday took action to lower drug costs by passing LD 1280, "An Act Regarding Drug Pricing," sponsored by Senate Democratic Leader Troy Jackson of Allagash. The FDA currently requires
6/23/17 - New Clopidogrel Therapy Study Findings Have Been Reported by Investigators at Eotvos Lorand University (Policy objective of generic medicines from...
New Clopidogrel Therapy Study Findings Have Been Reported by Investigators at Eotvos Lorand University. According to news originating from Budapest, Hungary, by NewsRx correspondents, research stated, "The objective of generic drug policies in most countries is defined from a disinvestment perspective: reduction in expenditures without compromising
6/23/17 - Study Findings from Metroplex Clinical Research Center Provide New Insights into Rheumatoid Arthritis (Efficacy and safety of the biosimilar ABP 501...
By a News Reporter-Staff News Editor at Drug Week Researchers detail new data in Autoimmune Diseases and Conditions- Rheumatoid Arthritis. According to news originating from Dallas, Texas, by NewsRx correspondents, research stated, "ABP 501 is a Food and Drug Administration- approved biosimilar to adalimumab; structural, functional and pharmacoki
6/22/17 - Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments
SUMMARY: The Food and Drug Administration is announcing the following meeting: "The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access." DATES: The meeting will be held on July 18, 2017, from 9 a.m. to 5 p.m. The deadline for submitting comments regarding this meeting is September 18, 2017. ADDRESSES: The meeting will be held
6/22/17 - Aiming for Amgen
The U.S. Supreme Court recently ruled that companies developing copies of these drugs, called biosimilars because exact generic copies can't be made, no longer must wait six months after getting regulatory approval to start selling them. Edward Jones analyst Ashtyn Evans says that will speed up competition for some Amgen medicines, which could redu
6/22/17 - Alembic Pharmaceuticals gets USFDA nod for Amantadine Hydrochloride Capsules [India Infoline News Service]
Alembic Pharmaceuticals on Thursday announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Amantadine Hydrochloride Capsules, USP, 100 mg. Alembic Pharmaceuticals on Thursday announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug.
6/22/17 - BRIEF: Teva loses $235m patent trial to GSK [Globes, Tel Aviv, Israel]
June 22 A US court yesterday ordered Teva Pharmaceutical Industries Ltd. to pay $235 million compensation to GlaxoSmithKline for violation of the latter's patent for its Coreg drug, used to treat chronic heart failure. The prevalent practice in the generic drug industry is for generic companies to attack a patent with a claim that it has expired,
6/22/17 - Erythropoietin (EPO) Drugs Market Forecast to 2025 - Analysis By Drug Class (Biologics, Biosimilars), Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), Application & Segment - Research and Markets
Research and Markets has announced the addition of the "Erythropoietin Drugs Market Analysis By Drug Class, By Product, By Application, And Segment Forecasts, 2014- 2025" report to their offering. For instance, in April 2016, Sandoz received approval from the European Commission for use of its biosimilar Binocrit in nephrology indications, thereby
6/22/17 - FDA accepts application for generic version of Advair Diskus
The FDA has accepted Sandoz's New Drug Application for fluticasone propionate / salmeterol combination product, a generic version of Advair Diskus...
6/22/17 - Lannett Receives Approval For Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg And 10 mg/300 mg
Lannett Company, Inc. today announced that it received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg, the therapeutic equivalent to the reference standard drug, Hydrocodone Bitartrate and Acetaminophe
6/22/17 - Sen. Grassley Encourages FDA Commissioner to Consider Proposals to Expand Access to Affordable Prescription Drugs
Gottlieb previously testified that the FDA would work to curtail gaming of FDA regulations by drug makers, improve the approval process for generic drugs and eliminate the FDA's backlog of applications for generics. The Creating and Restoring Equal Access to Equivalent Samples Act, which Grassley introduced with Senator Patrick Leahy, would address
6/21/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg
Release date- 20062017- PORT WASHINGTON, N.Y.- ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched an FDA approve
6/21/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg [Tehran Times (Iran)]
-ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched an FDA- approved generic version of Chlorthalidone Tablets,
6/21/17 - Alembic receives U.S. FDA approval for Candesartan Cilexetil Tablets [India Infoline News Service]
Alembic Pharmaceuticals has received US Food& Drug Administration approval for its Abbreviated New Drug Application for Candesartan Cilexetil Tablets, 32 mg, the company informed the bourses on Wednesday. Alembic Pharmaceuticals has received US Food& Drug Administration approval for its Abbreviated New Drug Application for Candesartan Cilexetil...
6/21/17 - Concordia International Corp. Provides Update on Development of Long-Term Growth Strategy
-Concordia International Corp., an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced an update on the development of its long-term growth strategy. To support the development and execution of this strategy, the Company has engaged Perella Weinberg Partners LP to provide financial..
6/21/17 - Credence Research: Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025
Global Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025. The latest market report published by Credence Research, Ltd. "Global Biosimilars Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017- 2025," the Biosimilars market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83
6/21/17 - FDA Voice Blog: FDA Working to Lift Barriers to Generic Drug Competition
While FDA doesn't have a direct role in drug pricing, we can take steps to help address this problem by facilitating increased competition in the market for prescription drugs through the approval of lower-cost, generic medicines. We could see even greater cost savings if we helped more safe and effective generic drugs get to market sooner, after p
6/21/17 - Grassley Encourages FDA Commissioner to Consider Proposals to Expand Access to Affordable Prescription Drugs
Gottlieb previously testified that the FDA would work to curtail gaming of FDA regulations by drug makers, improve the approval process for generic drugs and eliminate the FDA's backlog of applications for generics. The Creating and Restoring Equal Access to Equivalent Samples Act, which Grassley introduced with Senator Patrick Leahy, would address
6/21/17 - Olon SpA P&R Group Acquires Ricerca Biosciences Chemical Division In Ohio USA
By a News Reporter-Staff News Editor at Biotech Week Olon S.p.A., a world leading Active Pharmaceutical Ingredients contract development and manufacturing organization and Generics supplier, announced the acquisition of Ricerca Biosciences' Chemical Division of the contract research and CDMO based in Concord, Ohio, USA. This acquisition strengthe
Articles(s): 1 - 25 of 54     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415